CAYMAN PHARMA SRO

Overview

CAYMAN PHARMA SRO is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering ALPROSTADIL; BIMATOPROST; EPOPROSTENOL SODIUM; LATANOPROST; LATANOPROSTENE BUNOD; TAFLUPROST.

API / Drug Master Files

CAYMAN PHARMA SRO holds 7 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LATANOPROSTENE BUNODActive2023-05-30
• TAFLUPROSTActive2021-04-12
• LATANOPROSTActive2012-05-14
• BIMATOPROSTActive2011-01-10
• TRAVOPROSTActive2008-12-08
• EPOPROSTENOL SODIUMActive2008-04-28
• ALPROSTADILActive1992-05-13
• PROSTAGLANDIN E2 (DINOPROSTONE)Inactive1993-12-15

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CAYMAN PHARMA SRO in our records. PharmaTek screens the full directory against live FDA enforcement data.